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Abstract 
 
Rationale: Obsessive-compulsive disorder (OCD) implicates dysfunction of orbitofrontal and insula-
related circuitry and of the serotonin system.  There is an on-going search in psychiatry for 
intermediate biological markers, termed ‘endophenotypes’, that exist not only in patients with a given 
disorder but also in their clinically unaffected first-degree relatives.   
Objective: Pharmacological challenge is recognized as a means of eliciting an ‘endophenotype’ but 
this strategy has yet to be used in OCD.  
Methods: Twenty-three OCD patients without co-morbidities (n=23, 12 [52.2%] female), 13 clinically 
asymptomatic first-degree relatives of OCD patients (11 [84.6%] female), and 27 healthy controls (16 
[59.3%] female), received single dose escitalopram (20mg) and placebo in a randomized double-blind 
crossover design.  Effects of treatment on decision-making were quantified using the Cambridge 
Gamble Test (CGT) in conjunction with a mixed model ANCOVA.  
Results:  There was a significant interaction between serotonergic challenge and group for risk 
adjustment on the CGT (F=4.1406; p=0.02).  Only controls showed a significant placebo-drug change 
in risk adjustment (p=0.02; versus p>0.10). Numerically, escitalopram was associated with increase in 
risk adjustment in controls, and reductions in the other groups. Change in risk adjustment was similar 
in OCD patients and relatives (p=0.806) and differed significantly from controls (p=0.007; p=0.041 
respectively). No significant effects of serotonergic challenge, or challenge by group interactions, 
were found for the other task measures.  
Conclusions:  Individuals with OCD, and first-degree relatives, showed an altered cognitive response 
to serotonin challenge. We believe this to be the first demonstration of a candidate pharmacological 
challenge endophenotype for the disorder.  Future work should confirm these findings in a larger 
sample size, and ideally extend them to other cognitive paradigms, utilizing functional neuroimaging.  
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1. Introduction  
 
Obsessive-compulsive disorder (OCD) is characterized by recurrent and persistent ego-dystonic 
thoughts that are usually followed by repetitive and time-consuming behaviours aimed at reducing the 
distress, or undertaken according to rigid rules (American Psychiatric Association, 2013).  The 
prevalence of this disabling condition is between 2 and 3% (e.g. (Fontenelle et al., 2006; Ruscio et al., 
2010).  Generally, studies of OCD in adults have found either an equal distribution of men and 
women, or a slight predominance of women with this disorder.   
 
Serotonin reuptake inhibitors (SRIs) are considered safe and relatively effective first-line 
pharmacological treatments for OCD in adults (Lochner and Stein, 2015).  Response to 
pharmacotherapy in OCD has been mixed however, with 40-60% of patients exhibiting a lack of 
significant response to SRI (Bloch et al., 2006; Erzegovesi et al., 2001).  Nevertheless, there is a 
myriad of studies that have supported the hypothesis that the serotonin system may be dysfunctional 
in OCD (Pauls, 2010).  Although serotonin is the neurotransmitter most commonly implicated in OCD, 
direct support for a role for serotonin in the pathophysiology of OCD remains elusive (Goodman et al., 
2014).   
 
It is increasingly recognized that in order to optimize diagnostic classification systems and treatments 
for mental disorders, it is necessary to ‘look beyond’ top level symptoms and to consider 
neurobiological vulnerability markers.  Complex mental disorders such as OCD cannot easily be sub-
grouped into genetically homogeneous subtypes using symptoms or signs (phenotypical markers).  
Hence there is ongoing search in the neurosciences for endophenotypes that represent internal, 
intermediate traits or vulnerability markers for disease development and which lie closer to the genetic 
origins of the disorder under scrutiny (Gottesman and Gould, 2003).  So it can be said that an 
endophenotype is a heritable quantitative trait that is therefore present in both patients and their 
clinically unaffected relatives (Bearden and Freimer, 2006).  It cannot be seen ”by the unaided eye” 
and therefore requires technology to be accessed (Gottesman and Gould, 2003).  While the original 
definition of ‘endophenotypes’ recognized that they could be elicited by a behavioural (Gottesman and 
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Gould, 2003) or a pharmacological challenge such as one of the SRIs (Corregiari et al., 2012; Miller 
and Rockstroh, 2013), this latter strategy has been largely overlooked in OCD to date.   
  
OCD has been conceptualized by some as a disorder of decision-making (e.g. (Sachdev and Malhi, 
2005)), in part due to the centrality of obsessive doubting and uncertainty in this condition (Nikodijevic 
et al., 2015).  The cognitive process of doubt in OCD has been shown as the result of the dynamic 
interplay between the impact of possibility- and reality-based information, with OCD patients being 
significantly more affected by possibility-based information (Aardema et al., 2009).  Moreover, OCD 
patients seem to require more information and spend more time deliberating over scenarios before 
making a decision, compared to healthy controls (Banca et al., 2015; Foa et al., 2003).  It has been 
argued that the excessive doubt and uncertainty mediate such difficulties in decision-making (Foa et 
al., 2003).  In the study by Banca et al (2015) there was a differential influence of high and low 
uncertainty contexts on specific components of decision-making in OCD.  Patients required more 
evidence to reach a decision under conditions of high uncertainty.  In contrast, under conditions of low 
uncertainty, decision-making was slowed owing to poorer quality of evidence entering the decision 
process (Banca et al., 2015).  
 
Decision-making can be assessed using the Cambridge Gamble task (CGT), which is sensitive to 
abnormal decision-making in substance abuse, mania, and frontal lesions (Manes et al., 2002; 
Murphy et al., 2001; Rogers et al., 1999; Watkins et al., 2005).  Using the CGT, patients with 
comorbidity-free OCD, and their clinically asymptomatic first-degree relatives, did not show significant 
overt behavioral impairments on the CGT compared to healthy controls (Chamberlain et al., 2007a; 
Chamberlain et al., 2007b; Watkins et al., 2005).  This was contrary to expectations, because the task 
is dependent on orbitofrontal circuitry, and abnormalities of orbitofrontal circuitry are commonly 
reported in OCD (Menzies et al., 2008).  It should also be noted that one study did find decision-
making deficits in OCD using this task (Dittrich and Johansen, 2013), while other literature has 
reported deficits in OCD using other types of decision-making paradigms (e.g. (Cavedini et al., 2002; 
da Rocha et al., 2011)).  It may be argued that deficits detected by CGT are either subtle or variable 
in OCD, and may be more clearly seen if elicited with a pharmacological probe, or conceivably during 
symptom provocation.   
4 
 
 Several tiers of evidence suggest that serotonin manipulations, including over the short term, can 
impact aspects of decision-making (e.g. (Merens et al., 2007; Rogers, 2011); for discussion, see 
(Faulkner and Deakin, 2014)).  The direction of behavioral effect is likely to depend on many factors, 
including baseline serotonin status.  In a comprehensive review of the role of serotonin in various 
types of decision-making processes, it was suggested that serotonin promotes adaptive behaviour, 
with high central serotonin levels being associated with decision-making related behaviours 
(Homberg, 2012).  In previous work, acute tryptophan depletion – a technique that transiently 
diminishes brain serotonin – reduced quality of decision-making on the CGT in healthy volunteers 
(Rogers et al., 2003).  Elsewhere, it was shown the acute citalopram resulted in impaired reversal 
learning (ability to learn from feedback) in healthy volunteers, using a different type of task 
(Chamberlain et al., 2006).  Here, we were interested in exploring vulnerability markers for OCD using 
acute serotonin challenge and the CGT, given this task’s dependence on orbitofrontal and insula 
integrity, and serotonergic neurotransmission.  
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2. Methods 
 
The study comprised three groups of participants: patients with OCD (n=23, with 12 [52.2%] on 
chronic SRI treatment; all free from current clinically significant comorbid psychiatric disorders), 
clinically unaffected first-degree relatives of OCD patients (n=13, none on psychotropic medication; 
with no history of OCD), and healthy controls (n=27; with no current psychiatric disorder, nor any 
history of OCD).  The study was approved by the Institutional Review Board of the University of 
Stellenbosch, and all participants gave informed written consent to participate after risks and benefits 
had been explained. 
 
2.1 Clinical Assessments 
OCD patients were referred to our research unit from a wide range of sources (including the OCD 
Association of South Africa, community based primary care practitioners, and psychiatrists).  They 
were screened telephonically and subsequently interviewed by a clinical psychologist.  Patients met 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (American Psychiatric 
Association, 2000) criteria for a primary diagnosis of non-comorbid OCD.  The Mini International 
Neuropsychiatric Interview Plus (MINI Plus) – version 5 (Sheehan et al., 1998), a structured 
diagnostic interview developed for DSM-IV and ICD-10 psychiatric disorders, was used for diagnostic 
purposes.  All patients were also interviewed with the Structured Clinical Interview for Obsessive-
Compulsive Spectrum Disorders (SCID-OCSD) to determine the presence of comorbid obsessive-
compulsive spectrum disorders (du Toit et al., 2001).     
 
Patients were included however if they were either psychotropic medication free or on psychotropic 
medication that was 1) limited to a single psychotropic medication from the selective SRI-class of 
agents, 2) administered at a steady dose that was not higher than the optimal dose for OCD for the 
particular agent (e.g. 60mg of fluoxetine), 3) taken for at least 2 months (8 weeks), and 4) that was 
stabilized according to the treating psychiatrist.  Referring clinicians were contacted to help establish, 
where possible, a longitudinal expert assessment and diagnosis.  Patients with any clinically 
significant current psychiatric comorbidity or past history of significant substance or alcohol abuse 
were excluded from participation (n=31). 
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 First-degree relatives of OCD patients and controls were included if they had no current DSM-IV-TR 
disorder, nor any history of OCD.  Participants with OCD including those that we excluded from 
participation gave consent for a first-degree relative (parent or sibling) to be contacted, and these first-
degree relatives were enrolled into the study on the basis of freedom from psychiatric disorders 
including OCD.  Controls were recruited through advertisements in the local community and university 
intranet, and were entered into the study on the basis of freedom from psychiatric disorders including 
OCD, and having no known first-degree family members with OCD.  Two family members and 26 
controls were excluded due to diagnoses of current psychiatric disorders.   
 
Across all study participants, the 14-item Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1959), a 
measure of global anxiety, and the 10-item Montgomery-Asberg Depression Rating Scale (MADRS) 
(Davidson et al., 1986), a measure of severity of depressive symptomology, were administered to all 
participants.  In the OCD group, the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) (Goodman 
et al., 1989a; Goodman et al., 1989b) was administered to assess the severity of OCD symptoms.   
 
2.2 Pharmacological Challenge 
As noted earlier, serotonin manipulations may impact aspects of decision-making on the CGT and 
conceptually related tasks.  Participants received a single dose of one of the SSRIs, i.e. escitalopram 
(20mg), and placebo, in a double-blind, randomized, cross-over design.  The two study visits were 
separated by a minimum of 7 days in order to allow ample wash-out of escitalopram.  Three hours 
after administration of escitalopram or placebo, neurocognitive assessment of decision-making was 
undertaken as outlined below.  The rationale for using escitalopram was based on its pharmacokinetic 
profile, with peak plasma concentration levels (PPCLs) being expected 3-4 hours after oral dosing 
(Rao, 2007).  PPCLs of other the other SSRIs (all except citalopram) are generally much longer (e.g. 
sertraline, at 6-8 hours, fluoxetine, at 6-8 hours and fluvoxamine, at 4-12 hours).  Cognitive 
assessments took place during the PPCL phase (i.e. approximately 3-4 hours after administration). .  
 
2.3 Cognitive Assessment 
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Dissociable aspects of decision-making were investigated using the CGT, from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB: www.cambridgecognition.com).  For detailed 
descriptions of the task the reader is referred to previous validation studies (Clark et al., 2008; Manes 
et al., 2002).  The task was administered using a touch-screen computer in a quiet testing 
environment, supervised by a trained test administrator.  Although other tasks from the CANTAB were 
also performed, our analyses focused on CGT as performance on this type of task is sensitive to 
serotonin manipulations in healthy volunteers (Merens et al., 2007), and it may tap into neural 
substrates that tie in closely with those often implicated in OCD (the orbitofrontal cortices, and insula, 
for example) (e.g. (Chamberlain et al., 2008; Menzies et al., 2008; Saxena et al., 2001)).  
 
On the CGT, for each trial, subjects were presented with a row of ten boxes across the top of the 
screen, each box being blue or red.  Subjects were informed that the computer had hidden a ‘token’ 
behind one of these boxes, and that they had to first decide whether they believed the token to be 
hidden behind a red or blue box.  This decision was made by pressing a blue or red rectangle towards 
the bottom of the screen.  After making this choice, the participant had to gamble a proportion of their 
points as to whether they had made the correct color choice.  
 
Over the course of the task, the aim was to accumulate as many points as possible.  The proportion 
of red and blue boxes was varied pseudo-randomly, so that decision-making tendencies could be 
summarized across a spread of risk levels.  The outcome measures of interest on this task were:  
i) Overall proportion of points gambled;  
ii) Overall proportion of rational decisions made (the extent to which the participant indicated 
that the token was likely hidden behind a red box when red was in the majority, and behind 
the blue box when blue was in the majority); and 
iii) Risk adjustment (the extent to which participants modulated the amount gambled depending 
on the probability of making correct choices or by the ratio of boxes, with higher scores 
indicating greater sensitivity to risk). 
 
2.4 Statistical analysis 
Statistical analysis was undertaken using STATISTICA 12 (www.statsoft.com).   
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 Potential baseline group differences in clinical and demographic characteristics were explored using 
Analysis of Variance (ANOVA), with Fisher's LSD-tests used to explore significant main effects of 
group where identified (or equivalent non-parametric tests where appropriate, as indicated in the text).  
 
Cognitive data were analysed using separate mixed model Analysis of Covariance (ANCOVA) for 
each of the three outcome measures of interest.  The within-subject factors were order (placebo first 
or escitalopram first), and challenge (placebo or escitalopram), and the between-subject factor was 
group (OCD, OCD relatives, controls).  We subsequently compared the above outcome measures of 
interest between OCD patients taking SSRIs chronically and those not on any chronic psychotropic 
medication at the time of the assessments.  When significant effects were identified in an ANCOVA 
model, the nature of these effects was further explored using post hoc tests as appropriate (one-way 
ANOVA, t-tests, including for change scores).  Due to age differing between groups at baseline (see 
Results), age was entered as a covariate in the ANCOVA models.  
 
Statistical significance was defined as p<0.05 uncorrected.   
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3. Results 
 
Twenty-three OCD patients (n=23, 12 [52.2%] female), 13 unaffected first degree relatives of OCD 
patients (11 [84.6%] female), and 27 healthy controls (16 [59.3%] female) participated in the study.  
Most of the relatives were from independent families, and 3 were relatives of the OCD patients that 
participated in this study.  All participants were Caucasian.  The age range of participants was 18-59 
years (median 33 years).  
 
3.1 Demographic and Clinical Variables: 
As depicted in Table 1, the three groups did not differ significantly in terms of gender or IQ (both 
p>0.10).  However, groups differed in terms of age at entry (p<0.001); post hoc t-tests indicated that 
this was due to OCD relatives being older than the two other groups (versus OCD (p<0.001) and 
healthy controls (p=<0.001)).  
 
In terms of severity levels of anxiety and depressive symptomatology (Table 1), the groups differed 
significantly on both, as expected (both p<0.001).  Post-hoc tests indicated that this was due to OCD 
patients reporting significantly higher anxiety and depression levels than OCD relatives (p<0.001) and 
healthy controls (p<0.001).  OCD relatives and controls did not differ significantly from each other on 
these measures (anxiety: p=0.73; depression: p=0.89). 
 
OCD patients’ scores on the YBOCS ranged from 16 to 32, with a mean (SD) of 23.4 (4.5).  None of 
the controls nor the relatives reported any obsessions / compulsions, thus their scores (all 0) were not 
compared to that of the OCD group. 
 
Twelve out of the 23 OCD patients were receiving SSRI treatment at the time of study participation.  
According to participant reports and feedback from their treating psychiatrists, the SSRI treatment 
effects had stabilized for all of these participants.  However, patients were symptomatic enough in 
terms of their OCD to be included in the study (i.e. YBOCS total score >= 16), and all OCD relatives 
were free of any psychiatric diagnosis. 
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Table 1.  Demographic and clinical symptoms across groups 
Variable Groups Statistic p-value 
OCD patients 
N=23 
Healthy 
controls  
N=27 
OCD relatives 
N=13 
Mean age (SD) 32.74 (10.96) 31.37 (11.122) 46.85 (5.320) F=11.119 <0.001 
Gender Female N 
(%) 
12 (52.2%) 16 (59.3%) 11 (84.6%) Chi-square: 
4.228 
0.121 
Male  
N (%) 
11 (47.8%) 11 (40.7%) 2 (15.4%) 
WASI Full scale IQ 117 (11) 119 (11) 113 (10) F=1.113 0.349 
Mean HAM-A total (SD) 9.35 (4.677) 3.56 (3.401) 4 (2.915) F=15.869 <0.001 
Mean MADRS total (SD) 9.83 (5.167) 3.19 (3.064) 3.38 (2.931) F=20.285 <0.001 
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3.2 Cognitive results: 
i) Proportion of points gambled: On ANCOVA there was no significant main effect of 
group (F=3.0029; p=0.058) nor of challenge (F=0.3594; p=0.551) on this measure.  
The group by challenge interaction term was not significant (F=1.9733; p=0.149).  For 
raw data see Supplementary online table 1.  
 
ii) Proportion of rational decision-making: On ANCOVA there was no significant main 
effect of group (F=0.3624; p=0.698) nor of challenge (F=2.627; p=0.111) on this 
measure.  The group by challenge interaction term was not significant (F=1.5768; 
p=0.216).  For raw data see Supplementary online table 2.  
 
iii) Risk adjustment: On ANCOVA there was no main effect of group (F=1.0924; 
p=0.342), nor of challenge (F=0.1322; p=0.717) on this measure.  However, there 
was a significant group by challenge interaction (F=4.1406; p=0.02).  As can be seen 
in Figure 1, this significant interaction between group and treatment was due to risk 
adjustment reducing numerically in OCD patients and OCD relatives when on 
escitalopram, while the opposite effect was seen in the controls. The ANCOVA 
change within each group was significant only for controls (p<0.03; vs both other 
p>0.10). For raw data see Supplementary online table 3. 
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 Fig. 1 Risk adjustment scores across study groups* 
* Letters indicate post hoc differences at a 5% significance level, i.e. means without overlapping 
letters are significantly different (p<0.05). 
 
Using the change scores (i.e. the values obtained after administration of escitalopram minus the 
values that were obtained with placebo, per participant) to further characterize the causes of the 
interaction effect (group x treatment), it was found that the effect of escitalopram challenge on the 
change scores for risk adjustment differed significantly across diagnostic groups (F(2.56)=3.512, 
p=0.037) (Figure 2).  Post-hoc t-tests indicated that change scores did not differ significantly between 
OCD patients and their relatives (p=0.806); while the differences between these two groups and 
controls were significant (OCD vs. controls: p=0.007, effect size: 0.79: OCD relatives vs. controls: 
p=0.041, effect size: 0.77).   
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 Fig. 2 Change scores for risk adjustment differ significantly across diagnostic groups* 
* Letters indicate post hoc differences at a 5% significance level, i.e. means without overlapping 
letters are significantly different (p<0.05). 
 
The change in risk adjustment scores (means, SDs) on the CGT are summarized in Table 2.  Post 
hoc t-tests suggested that escitalopram challenge had a similar effect in OCD patients and OCD 
relatives (p=0.804), i.e. to decrease risk adjustment, compared to the increase noted in the healthy 
controls.   
 
Table 2. Change in mean risk adjustment scores across study groups 
Diagnostic group N Mean Std. Deviation 
OCD patients 23 -0.25 .735 
OCD relatives 13 -0.19 .590 
Healthy controls 27 0.29 .663 
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 Given the relatively uneven distribution of genders across groups (i.e. 52.2% of OCD patients, 59.3% 
of controls, and 84.6% of relatives were female, respectively; p=0.121), analyses of risk adjustment 
data were repeated with males excluded.  Smaller sample size reduced power; the results 
nevertheless showed similar tendencies than in the whole sample although these were not significant 
(p=0.21).  (See Supplementary online figures 1 and 2).  
 
Subsequent analyses showed that the extent and direction of changes on the CGT remained the 
same when the above outcome measures of interest were compared between OCD patients taking 
SSRIs chronically and those not on any chronic psychotropic medication at the time of the 
assessments.  More specifically, prior medication status did not impact risk adjustment or the effect of 
escitalopram challenge on risk adjustment in OCD patients.    
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4. Discussion 
 
As noted earlier, endophenotypes, as quantifiable traits lying on the causal chain between a clinical 
phenotype and aetiology (Shaw et al., 2015), can be elicited by behavioural and/or pharmacological 
challenge.  Here, we applied both strategies.  We found that patients with OCD and unaffected first-
degree relatives of patients with OCD showed a similar, altered response to acute serotonin 
challenge.  Specifically, escitalopram (SSRI) challenge led to significant increases in risk adjustment 
on the gambling task in healthy controls, and this effect was absent in the OCD patients and relatives.  
We believe this to be the first demonstration of a candidate endophenotype for OCD that can be 
elicited by pharmacological challenge.   
 
Finding stable endophenotypes is valuable in that it makes genetic and biological studies of the 
aetiologies for disease categories more manageable than using heterogeneous psychiatric symptoms 
or phenotypes (Gould and Gottesman, 2006).  A fundamental assumption of the endophenotype 
concept is that the proposed marker genetically heritable (Gottesman and Gould, 2003).  Our findings 
here suggest that patients with OCD and unaffected first-degree relatives of patients with OCD 
showed a similar discrepancy from controls in the effect of escitalopram on risk adjustment, alluding 
to the heritability of the identified endophenotype.  It may, on the other hand, be argued that variance 
(between OCD patients/OCD relatives and controls) could be due to environmental influences with 
OCD patients and relatives sharing environments.  Future work would need to replicate this result and 
show whether the absence of response to serotonin challenge is significantly heritable.   
 
The CGT, and other decision-making tasks, are dependent on distributed neural circuitry linked with 
the processing of aversive outcomes and reward.  Using the CGT, it has been demonstrated that 
patients with lesions to the insular cortex failed to adjust their bets by the odds of winning, i.e. showed 
dampened risk adjustment.  This pattern of abnormal performance on the task was different from that 
observed in patients with damage to other cortical regions including the ventromedial / lateral 
prefrontal cortices (e.g. (Clark et al., 2003; Clark et al., 2008).  It should be noted, however, that insula 
damage affected not just risk adjustment but also betting behaviour, in that insular damage was also 
associated with participants gambling a greater proportion of their points overall (Clark et al., 2008).  
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The dorsal and median raphe nuclei represent the source of most serotonergic projections in the 
brain, and show strong functional connectivity with regions including the insula (Beliveau et al., 2015).  
The insula, and other regions including the lateral orbitofrontal cortices, play a cardinal role in 
evaluating negative outcomes (Liu et al., 2007).  Data from a functional neuroimaging pharmaco-fMRI 
challenge study in healthy controls indicates that serotonin 2A receptors modulate the evaluation of 
‘missed’ rewards, i.e. one type of negative outcome (Macoveanu et al., 2013).  In the recent study by 
Worbe et al (Worbe et al., 2015), reducing serotonin neurotransmission in healthy controls using 
acute dietary tryptophan depletion led to impairment of specific goal-directed aspects of decision-
making related to gaining a reward, whereas these aspects of decision-making were promoted under 
the risk of punishment.  The authors suggested this differential effect on appetitive and aversive goal-
directed behaviour is likely mediated by alteration of the representation of reward produced by 
serotonin depletion.  
 
Thus, one plausible explanation for our findings in healthy controls is that acute blockade of serotonin 
reuptake by a single dose of escitalopram led to enhanced sensitivity to negative outcomes, which in 
turn contributed to greater adjustment of gambling behaviour as a function of risk of loss.  In the 
absence of fMRI, the neural mechanism of the effects of serotonin challenge on this component of 
decision-making we observed are unclear, but could reflect serotonergic modulation of the insula.  
This could be explored in future pharmaco-fMRI work.  The absence of a significant effect of serotonin 
reuptake inhibition on risk adjustment common to OCD patients and asymptomatic relatives is 
indicative of a pre-existing abnormality of the serotonin system that may predispose towards OCD.  
Data from studies showing the selective response to treatment with serotonin reuptake inhibitors, the 
transient exacerbation of OCD symptoms when challenged with serotonergic agonists such as mCPP 
and sumatriptan, and a role for biological markers of serotonergic function in OCD, for example, have 
over the years reinforced the idea that this condition is associated with a disruption in the serotonin-
neurocircuitry (e.g. (Barr et al., 1992)).  Chronic treatment with SSRIs have been associated with 
remediation of some neuropsychological deficits in some OCD (Andres et al., 2008); however, here 
administration of a serotonergic agent was associated with the absence of a significant change in risk 
adjustment in OCD patients and relatives which may reflect on the compromised serotonin-
neurocircuitry not responding to acute challenge.   
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 In terms of limitations, the study focused on a few aspects of decision-making which may be affected 
by serotonin manipulations.  Additional related cognitive variables could have been added to the 
analyses; however, it was decided to include three outcome measures of interest on the CGT in order 
to reduce the number of comparisons.  The relatively small sample size constitutes a limitation; 
however, the relatively large effect sizes (e.g. using the change scores [Figure 2; Table 2]: OCD vs. 
controls; OCD relatives vs. controls) were comforting.  The OCD relatives group was smaller than the 
other two study groups, but still exhibited a significant difference versus controls in terms of change 
scores, suggesting that the group was nonetheless large enough to detect group differences (i.e. was 
adequately powered). While the OCD relatives groups had numerically a higher proportion of females 
(not statistically significant), we did not find any significant effect of gender on CGT performance 
overall.  In terms of age, the decline in cognitive function with aging is well established (e.g. (De Luca 
et al., 2003; Sliwinski and Buschke, 1999)).  Some of the CANTAB tests (not the CGT) have also 
revealed significant cognitive decline as a function of age (e.g. (Rabbitt and Lowe, 2000)).  In our 
analyses, age was entered as a covariate in the analyses given the fact that the relatives were much 
older than the other two study groups; therefore the key findings appeared robust to this confound, as 
far as could be ascertained.  Another potential limitation is the fact that our OCD sample was 
heterogeneous in terms of their OC symptoms, i.e. patients with specific OC symptom subtypes may 
be more prone to risk taking or vice versa (Lochner et al., 2005). The fact that OCD patients receiving 
SSRI medication were not withdrawn from participation can also be construed as a limitation.   
Finally, here we focused on the CGT but other decision-making tasks are available, some of which 
have shown abnormal cognitive functioning in relatives of OCD patients (Cavedini et al., 2010).  It 
would be valuable for future work to address the impact of serotonin challenge on cognition in OCD 
and relatives of patients using alternative tasks.  
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5. Conclusion 
 
In summary, there are very few studies that have investigated the effects of acute SSRI administration 
on selected cognitive functions in humans, and most of these have focused on healthy volunteers.  
Our study is, to our knowledge, the first to investigate the effects of acute SSRI administration on 
decision-making in OCD patients, first-degree OCD relatives and healthy controls in an attempt to 
accurately identify another useful OCD endophenotype.  This is important given that the discovery of 
novel candidate brain function endophenotypes may increase the power of candidate gene and 
genome-wide association studies.  Future studies should aim to replicate these findings, in larger 
cohorts, and examine the stability and utility of the hypothesized endophenotype in OCD and -related 
conditions, ideally incorporating fMRI. 
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